Phase III trial of chemotherapy ? HerceptinR in metastatic breast cancer

Breast Cancer Research ◽

10.1186/bcr-2001-68448 ◽

2001 ◽

Vol 3 (1) ◽

Author(s):

Fatima Cardoso

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Trial

Download Full-text

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial

British Journal of Cancer ◽

10.1038/sj.bjc.6603096 ◽

2006 ◽

Vol 94 (9) ◽

pp. 1233-1236 ◽

Author(s):

C Pacilio ◽

◽

A Morabito ◽

F Nuzzo ◽

A Gravina ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Adjuvant Treatment ◽

Metastatic Breast ◽

Phase Iii ◽

Single Centre ◽

Phase Iii Trial ◽

Line Chemotherapy

Download Full-text

A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study

Annals of Oncology ◽

10.1093/annonc/mdw077 ◽

2016 ◽

Vol 27 (6) ◽

pp. 1020-1029 ◽

Author(s):

O. Trédan ◽

P. Follana ◽

I. Moullet ◽

C. Cropet ◽

S. Trager-Maury ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Maintenance Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Trial

Download Full-text

Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer

Yearbook of Oncology ◽

10.1016/s1040-1741(10)79503-8 ◽

2010 ◽

Vol 2010 ◽

pp. 28-29

Author(s):

J.T. Thigpen

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Independent Review

Download Full-text

OT2-01-02: First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase III Trial.

10.1158/0008-5472.sabcs11-ot2-01-02 ◽

2011 ◽

Author(s):

S Beslija ◽

T Brodowicz ◽

R Greil ◽

MJ Inbar ◽

Z Kahán ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Locally Recurrent

Download Full-text

Abstract S5-07: SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment

10.1158/0008-5472.sabcs13-s5-07 ◽

2013 ◽

Author(s):

JB Smerage ◽

WE Barlow ◽

DF Hayes ◽

EP Winer ◽

B Leyland-Jones ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Metastatic Breast ◽

Circulating Tumor Cell ◽

Phase Iii ◽

Breast Cancer Patients ◽

Phase Iii Trial

Download Full-text

Abstract P1-18-01: Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: A non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks: SAKK 96/12 (REDUSE)

10.1158/1538-7445.sabcs18-p1-18-01 ◽

2019 ◽

Author(s):

A Müller ◽

AJ Templeton ◽

S Hayoz ◽

H Hawle ◽

U Hasler-Strub ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Trial

Download Full-text

Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifen

Cancer ◽

10.1002/1097-0142(19940115)73:2<354::aid-cncr2820730220>3.0.co;2-j ◽

1994 ◽

Vol 73 (2) ◽

pp. 354-361 ◽

Author(s):

Kenneth E. Gale ◽

Janet W. Andersen ◽

Douglass C. Tormey ◽

Edward G. Mansour ◽

Thomas E. Davis ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Eastern Cooperative Oncology Group ◽

Metastatic Breast ◽

Hormonal Treatment ◽

Phase Iii ◽

Oncology Group ◽

Phase Iii Trial

Download Full-text

First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.515 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 515-515 ◽

Author(s):

R. Paridaens ◽

P. Therasse ◽

L. Dirix ◽

L. Beex ◽

M. Piccart ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Hormonal Treatment ◽

Phase Iii ◽

Phase Iii Trial ◽

Download Full-text

Cardiac toxicity prevention in non-metastatic breast cancer patients treated with anthracycline-based chemotherapy: A randomized, placebo controlled, phase III trial—SAFE trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps1100 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS1100-TPS1100 ◽

Author(s):

Icro Meattini ◽

Roberto Tarquini ◽

Calogero Saieva ◽

Alice Valoriani ◽

Pierluigi Bonomo ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Cardiac Toxicity ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Phase Iii Trial

Download Full-text

Randomized phase III trial of utidelone, a genetically engineered epothilone analog, in combination with capecitabine versus capecitabine alone for metastatic breast cancer patients with previous taxane and anthracycline treatment.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.1004 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 1004-1004

Author(s):

Binghe Xu ◽

Tao Sun ◽

Qingyuan Zhang ◽

Zhongyu Yuan ◽

Pin Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Metastatic Breast ◽

Genetically Engineered ◽

Phase Iii ◽

Breast Cancer Patients ◽

Phase Iii Trial

Download Full-text